• CYPIDES Study Details | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer | ClinicalTrials.gov (HUS, TAYS)
• RADIANT Study Details | Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH | ClinicalTrials.gov (TAYS, OYS)
• Keynote-365 Study Details | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | ClinicalTrials.gov (TAYS)
• Primordium Study Details | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | ClinicalTrials.gov (TAYS)
• KuPSMALu-177 FICAN East | Itäinen Syöpäkeskus (KYS)
• BAY 3546828 – ACTINIUM A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
• OMAHA-1 Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (KYS, TAYS, TYKS)

Keuhkosyöpä

• ASTEROID Study Details | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) | ClinicalTrials.gov (HUS, TAYS, TYKS)
• DART Study Details | Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study | ClinicalTrials.gov (TAYS, OYS)
• SPARTA Study Details | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | ClinicalTrials.gov (TAYS)
• GSK 213824 Study Details | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | ClinicalTrials.gov (TAYS)
• COSTAR Study Details | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy | ClinicalTrials.gov (TAYS)
• KontRASt-02 Study Details | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | ClinicalTrials.gov (TYKS)

Lymfoomat

• POLAR BEAR Study Details | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma | ClinicalTrials.gov (HUS, KYS, OYS, TAYS, TYKS)
• FirmMind Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) – Full Text View – ClinicalTrials.gov (HUS, KYS, OYS, TAYS, TYKS)
• EPCORE™ NHL-2 Study Details | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | ClinicalTrials.gov (HUS, KYS)
• EPCORE™ NHL-1 Study Details | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | ClinicalTrials.gov (HUS, KYS, TAYS)
• BBBD-01 Clinical Trials Register (OYS)
• POLARGO Study Details | A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | ClinicalTrials.gov (OYS, TAYS)
• ALTAMIRA Study Details | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma | ClinicalTrials.gov (HUS, KYS, OYS, TAYS)
• EPCORE DLBCL-1 Study Details | A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL | ClinicalTrials.gov (HUS, OYS)
• MERLIN Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries – Full Text View – ClinicalTrials.gov (HUS)
• Hutchison-2018–532-00US1 Study Details | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | ClinicalTrials.gov (HUS, TAYS)

Maksasyöpä

• IMbrave251 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251) (Docrates, TAYS, TYKS)

Melanooma

• STARBOARD A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma (HUS, TAYS)
• CA224-127 A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) (HUS, TAYS, TYKS)

Munuaissyöpä

• MK-6482-022 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) (HUS, KYS, OYS, TAYS, TYKS)

Pään ja kaulan alueen syövät

• NANORAY NBTXR3 With or Without Cetuximab in LA-HNSCC (TAYS)

Rintasyöpä

• EPIK-B5 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/​6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5) (HUS, TAYS)
• HER2CLIMB-05 A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) (HUS, KYS, TAYS, Vaasa)
• VERITAC-2 A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2) (OYS, Pori, TAYS, Vaasa)
• AL-2001-IXABEPILONE Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. (TAYS)
• IMPORTANT Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/​6-inhibitors in Older Breast Cancer Patients (IMPORTANT) (HUS)
• INAVO-122 A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (TAYS, TYKS)

Suolistosyöpä

• BREAKWATER A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (HUS, OYS, TAYS, TYKS)
• AZUR-2 Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/​MSI-H Resectable Colon Cancer (AZUR-2) (HUS, TAYS, TYKS)
• SYNCOPE Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer (SYNCOPE) (HUS, TAYS)

Useat syöpätyypit

• FINPROVE The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE) (HUS, KYS, TAYS, TYKS)
• TUNIMO TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (TUNIMO) (HUS, Docrates)